Table 5.
Subgroup analyses of DBP in Clinically Meaningful Subsets.
| Groups | Number of Patients | Events | Crude | p for interaction | Adjusted * | p for interaction | ||
|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | p-value | HR (95%CI) | p-value | |||||
| Etiology | 0.812 | 0.709 | ||||||
| Organic TR | 686 | 51 | 0.81 (0.64–1.03) | 0.091 | 0.78 (0.61–0.99) | 0.045 | ||
| Functional TR | 1,025 | 78 | 0.76 (0.63–0.90) | 0.002 | 0.78 (0.66–0.92) | 0.003 | ||
| Other | 129 | 13 | 0.86 (0.55–1.35) | 0.512 | 0.95 (0.61–1.46) | 0.808 | ||
| NYHAc | 0.276 | 0.074 | ||||||
| NYHA < III | 1,300 | 54 | 0.90 (0.72–1.12) | 0.341 | 0.95 (0.75–1.20) | 0.658 | ||
| NYHA≥III | 548 | 111 | 0.78 (0.68–0.89) | <0.001 | 0.73 (0.62–0.86) | <0.001 | ||
| LVEF | 0.521 | 0.241 | ||||||
| LVEF <50 | 289 | 55 | 0.82 (0.68–0.99) | 0.036 | 0.87 (0.71–1.07) | 0.196 | ||
| LVEF≥50 | 1,559 | 110 | 0.76 (0.65–0.89) | <0.001 | 0.74 (0.63–0.88) | <0.001 | ||
| ACEI/ARB | 0.434 | 0.667 | ||||||
| Yes | 740 | 61 | 0.85 (0.70–1.02) | 0.077 | 0.77 (0.61–0.97) | 0.024 | ||
| No | 1,273 | 104 | 0.76 (0.65–0.90) | 0.002 | 0.82 (0.69–0.97) | 0.018 | ||
| Diuretic | 0.198 | 0.805 | ||||||
| Yes | 1,191 | 135 | 0.85 (0.75–0.96) | 0.012 | 0.80 (0.69–0.92) | 0.002 | ||
| No | 822 | 30 | 0.68 (0.49–0.93) | 0.017 | 0.76 (0.53–1.09) | 0.131 | ||
*
Adjusted for age, sex, BMI, diabetes, CAD, PH, eGFR, severe TR, LVEF, LVEDDi, NYHAc, and etiology when they were not the strata variables. BMI, body mass index; CAD, coronary heart disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEDDi, indexed left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension; TR, tricuspid regurgitation.